Italia markets open in 8 hours 10 minutes

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
42,13+0,20 (+0,48%)
Alla chiusura: 04:00PM EST
42,13 0,00 (0,00%)
Dopo ore: 04:51PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente41,93
Denaro42,10 x 800
Lettera42,25 x 1000
Min-Max giorno41,91 - 42,56
Intervallo di 52 settimane36,15 - 44,75
Media Volume1.675.703
Beta (5 anni mensile)0,35
Rapporto PE (ttm)36,96
EPS (ttm)1,14
Prossima data utili13 feb 2023 - 17 feb 2023
Rendimento e dividendo (forward)0,76 (1,77%)
Data ex dividendo17 nov 2022
Stima target 1A54,07
  • GlobeNewswire

    Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

    NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022 at 10:30 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma

  • GlobeNewswire

    Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

    Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasd

  • GlobeNewswire

    Royalty Pharma Reports Third Quarter 2022 Results

    Net cash provided by operating activities (GAAP) of $539 million and Adjusted Cash Receipts(1) (non-GAAP) of $597 million Announced transactions of up to $3.0 billion year-to-date, including $1.7 billion in upfront payments Increased 2022 guidance: Adjusted Cash Receipts(1) expected to be $2,750 to $2,800 million, which includes $458m from the acceleration of payments related to Pfizer’s acquisition of Biohaven NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today r